Cytovance Biologics
Related Content
-
Breaking News | Industry News | Promotions & Moves
Forge Biologics Expands Leadership Team
Announces two key hires in process development and medical affairs.08.30.21
-
Bio News | Breaking News | Industry News | Promotions & Moves
Vibalogics Advances Growth with Leadership Hires
Pharma industry vet Roger Lias joins the CDMO as chief commercial officer.07.16.21
-
Bio News | Breaking News | Industry News
Cytovance Biologics Offers Licensing for Plasmid DNA Manufacturing
The Keystone Expression System pDNA platform is an end-to-end solution for manufacturing GMP pDNA at scale.Tim Wright, Editor, Contract Pharma 03.09.21
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
Cytovance Expands Partnership with Nature Technology Corp.
Now offers NTC’s proprietary HyperGRO manufacturing platform for plasmid DNA CGMP manufacturing.Contract Pharma Staff 12.03.20
-
Breaking News | Industry News | Promotions & Moves
Cytovance Appoints CEO
Bin Zhang has been with Cytovance as a member of the Board of Directors since 2018.Contract Pharma Staff 11.12.20
-
Breaking News | Industry News | Promotions & Moves
Vigene Biosciences Appoints COO
Molly McGlaughlin brings 27 years of experience in biologics manufacturing and development.Contract Pharma Staff 10.15.20
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
GT Biopharma and Cytovance Biologics Expand Partnership
Cytovance will be the exclusive GMP manufacture for three of the company's TriKE therapeutic product candidates.Contract Pharma Staff 10.06.20
-
Breaking News | Industry News | Promotions & Moves
Cytovance Appoints VP of Biz Dev and Marketing
Mathew Delaney joins the senior leadership teamContract Pharma Staff 05.04.20
-
Process Development for Scaled-up hESC/hiPSC Manufacturing
An optimized 14-day manufacturing workflow which produces > 10^10 , cells was developed in < 12 months
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News
Avantor Boosts Biopharmaceutical Innovation in China
Opens innovation and customer support center in Shanghai.12.11.19
-
Bio News | Bioanalytical Services | Breaking News | Facilities | Industry News
Horizon Therapeutics Expands Capabilities
Opens new manufacturing and R&D facility in South San Francisco.11.26.19
-
Frontage Laboratories' Hugh Davis
Frontage's chief business officer highlights the CRO's service offerings.Contract Pharma Staff
-
Catalent's Stacey Treichler
Catalent's product manager for biologics highlights key events.Contract Pharma Staff
-
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News
Cytovance Expands Gene Therapy Service Capabilities
Introduces an integrated single-use platform for plasmid DNA manufacture at Oklahoma facility.10.23.19
-
APIs
Better Drug Manufacturing Strategies: Custom APIs
Today’s biopharma companies are turning to their contractors for long-term collaboration and much higher levels of support.Tom Wilson, VP, Global Contract Manufacturing Leader, Pfizer CentreOne 10.15.19
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
Prevail, Lonza Enter Development and Mfg. Alliance
Lonza will manufacture Prevail's AAV-based gene therapy programs for neurodegenerative diseases10.08.19
-
-
Cytotoxics and High Potency Manufacturing
API to ADC: A Journey Through High Potency
This class of compounds represents a major advance in oncology research and treatment application.Maurits Janssen, Head Commercial Development API, Lonza Pharma & Biotech 09.16.19
-
Current Trends and Emerging Needs for Microbial Fermentation
Over the last decade, the potential of fermentation-based manufacturing has expanded dramatically due to advances in synthetic biology and genetic engineering.
-
Industry News | Process Development
Cambrex Expands Process Development at Edinburgh Facility
Doubles current footprint to 15,000 sq. ft., adding lab space to accommodate 40 more scientists07.30.19
-
Collaborations & Alliances | Drug Development
Gilead and Nurix to Collaborate on Novel Therapies
Consisting of targeted protein degradation drugs for patients with cancer and other challenging diseases06.20.19
-
Bio News | Breaking News | cGMP Manufacture | Facilities | Industry News | Inspections
Cytovance Completes Second FDA PAI of Oklahoma Facilities
Demonstrates capabilities and cGMP compliance in manufacturing commercial products06.18.19
-
Bio News | Industry News | Promotions & Moves
-
Bio News | Collaborations & Alliances | Drug Development | Industry News
Cytovance, Horizon Sign License Agreement
For the use of their HD-BIOP3 Suspension adapted GS null CHO K1 cells10.03.18
-
Bio News | Industry News | Promotions & Moves
Cytovance Names New CEO
Dr. Yan Wang has been with the company for three years, and has over two decades of industry experience07.31.18
-
Bio News | Industry News | Inspections
Cytovance Biologics Completes FDA Inspection
The successful five-day process focused on quality systems, facilities, maintenance programs and manufacturing05.09.18
-
Promotions & Moves
Paragon Bioservices Makes Key Appointments
Appoints chief commercial officer, chief manufacturing officer, and chief scientific officer01.25.18
-
Promotions & Moves
-
Promotions & Moves
-
cGMP Manufacture | Clinical Trial Materials | Industry News | Scale-up/Technology Transfer
Cytovance to Manufacture Bexion’s First Clinical Compound
To manufacture the protein component and active ingredient for BXQ-350 to support Phase II trials11.28.17
-
Industry News | Inspections
Cytovance Completes FDA Inspection at Oklahoma City Facilities
Takes action to address facility updates and improvements07.24.17
-
Promotions & Moves
Cytovance Biologics Names Bioprocess Development VP
Dr. Mott brings more than 30 years of experience02.28.17
-
Breaking News | Promotions & Moves
Cytovance Names Senior VP of Mfg.
Mike O’Mara takes over with more than 23 years of biopharma contract mfg. experience01.20.17
-
Promotions & Moves
Paragon Bioservices Names Project Management VP
Adams brings more than 30 years of industry experience08.10.16
-
Process Development | Validation
Cytovance Appoints Mfg. SVP
Maddalo brings 30 years of experience manufacturing commercial cGMP products04.26.16
-
Biologics, Proteins, Vaccines | Drug Discovery | Industry News | Process Development | Scale-up/Technology Transfer
Cytovance Expands Keystone Expression System
Platform aims to address obstacles for researchers using E. coli03.10.16
-
Process Development | Promotions & Moves
PacificGMP Makes Two Senior Appointments
Will support the growth that PacificGMP has continued to make since joining Abzena01.29.16
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
Cytovance, NeuroFx Enter Development and Mfg. Pact
To deliver a robust process for cell-free therapy to treat neurological conditions07.30.15
-
Breaking News | Promotions & Moves | R&D | Validation
Cytovance Appoints COO
Wuchterl to oversee R&D services, manufacturing, engineering, and program management12.09.14
-
Breaking News | Promotions & Moves | Regulatory Affairs
-
Breaking News | Clinical Trial Materials | Industry News
-
Breaking News | Capsules | Clinical Trial Materials | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Industry News | Lyophilization | Process Development
-
Biologics, Proteins, Vaccines | Breaking News | Capsules | Clinical Trial Materials | Collaborations & Alliances | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development
Cytovance, Precision Biologics Expand Mfg. Pact
To provide additional cGMP manufacturing services to support Phase II trials of NEO-102Kristin Brooks 03.25.14
-
Bio News | Bioassay Development | Biologics, Proteins, Vaccines | Breaking News | Capsules | Clinical Trial Materials | Collaborations & Alliances | Drug Development | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Methods Development | Process Development | Toxicology
Cytovance, Pamlico in Dev., Mfg. Pact
Will provide mammalian, microbial services to clinical-stage companyGil Roth 02.18.14
-
Breaking News | Process Development | Promotions & Moves
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development | Vials
-
Breaking News | Promotions & Moves | Regulatory Affairs
-
Breaking News | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Industry News | Lyophilization | Process Development
-
Breaking News | Promotions & Moves | Validation
-
Breaking News | Clinical Trial Materials | Industry News
-
Breaking News | Drug Discovery | Promotions & Moves
-
Analytical Services | Aseptic Processing | Bioanalytical Services | Bioassay Development | Biologics, Proteins, Vaccines | Biosimilars | Capsules | Clinical Trial Materials | Clinical Trials | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development | Process Validation | Scale-up/Technology Transfer | Toxicology
Bio-CMO Industry Trends
Recent initiatives in biopharma contract manufacturingWilliam Downey, HighTech Business Decisions 05.04.12
-
Breaking News | Promotions & Moves
Cytovance Biologics Adds to Leadership Team
Vaillant, Ernst and McDonnell join finance, operations and business development03.14.12
-
Breaking News | Promotions & Moves
Cytovance Biologics
Bernhard Hampl, Ph.D., has been appointed co-chairman of Cytovance Biologics, Inc.04.25.11
-
Breaking News | Industry News
Cytovance to Expand Bio-Manufacturing Capabilities
Cytovance Biologics has secured financing of $22.5 million from Great Point Partners, LLC to invest in the expansion its biologic manufacturing capabilities in Oklahoma City.03.15.11
-
Breaking News | Industry News
Cytovance Biologics Wins Selexys Contract
Cytovance Biologics and Selexys Pharmaceutical have entered an agreement for the execution of a biopharmaceutical development and manufacturing collaboration for Anti-PSGL-1, a monoclonal antibody (mAb) being developed for treatment of inflammation associ04.26.10
-
Breaking News | Promotions & Moves
-
Breaking News | Packaging & Tracking | Process Development | Regulatory Affairs
Cytovance Biologics
Jeffrey Su, Ph.D., has been named vice president of bioanalytical development at Cytovance08.31.09
-
Breaking News | Promotions & Moves
-
Breaking News | Industry News | Process Development
-
Breaking News | Promotions & Moves
